Lateral Flow Assays Market

Lateral Flow Assays Market by Product (Kits, Readers), Application (Clinical Testing, Veterinary Diagnostics, Food Safety & Environmental Testing), Technique (Sandwich, Multiplex Detection Assay), End User (Hospitals, Home care) & Region - Global Forecast to 2027

Report Code: MD 4158 Feb, 2023, by marketsandmarkets.com

Updated on : February 15, 2023

The global lateral flow assays market in terms of revenue was estimated to be worth $20.5 billion in 2022 and is poised to reach $22.6 billion by 2027, growing at a CAGR of 2.0% from 2022 to 2027. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.

Increasing adoption of kits & reagents and lateral flow assay readers for infectious diseases testing, veterinary diagnostics, and drug of abuse testing, cardiac marker testing. Whereas most of lateral flow assays are having limitation of qualitative detection, lot to lot variation like factors may hinder the growth of global market during the forecast period.

Global Lateral Flow Assays Market Trends

Lateral Flow Assays Market

To know about the assumptions considered for the study, Request for Free Sample Report

Impact of economic recession on Lateral Flow Assays Market

To assess the impact of economic recession and provide market forecasts, scenario-based approaches are considered.

There has been a sharp rise in the consumer price index (CPI) globally over the past year. According to an article published by the American Animal Hospital Association (AAHA), CPI has increased by 7.1% in the US since December 2020 (it has been the fastest annual rise since 1982). This increase in prices is affecting almost every business sector—including the medical device space, where inflation has led to increases in laboratory diagnostics and vendor fees, as much as 12% in some cases.

To counter the rising inflation, central banks across the world have increased their lending rates. But these counter-inflation measures could decrease the global GDP growth by 0.4%—settling down to 0.5% in 2023 (Source: World Bank)—which would meet the technical definition of a recession. This would impact health expenditure and thus negatively impact all healthcare product and service markets, including the lateral flow assay market.

Lateral Flow Assays Market Dynamics

DRIVER: Need for rapid diagnostics testing for COVID-19

The need for rapid diagnosis for treatment will increase with the rising number of COVID-19 cases globally, and data collection is expected to accelerate the growth of the global market in the forecast period.

The advantages of lateral flow assay tests in detecting COVID-19 antibodies include their affordability, ease of interpretation, and speedy diagnosis (within 15 minutes). Since these tests can also be produced economically, all the major players in the lateral flow assay market launched COVID-19 tests in the past year. For instance,

  • In October 2022, Roche Diagnostics launched the SARS-CoV-2 Rapid Antigen Test 2.01, SARS-CoV-2 Rapid Antigen Test 2.0 Nasal2, and SARS-CoV-2 Rapid Antigen Test 2.0 Nasal3.
  • In September 2020, Abbott Laboratories (US) launched the PANBIO COVID-19 IgG/IgM Rapid Test Device in Europe.

Growing demand for point-of care testing

The the growing demand of point-of care testing uis mainly due to rising prevalence of chronic disease, technological advancements, and gowing people awareness. Major companies are focusing on developing a products with good sensitivity and performance for application such as pregnancy testing, COVID-19 testing, and cardiac marker testing.

Inconsistent results of lateral flow assays tests

Although easy to perform and more economical than laboratory tests, lateral flow assay tests have been observed to have lower accuracy. As per Mayo Clinic, while using pregnancy kits, false-positive results may happen if the patient had a pregnancy loss soon after the fertilized egg attached to the uterine lining (biochemical pregnancy); consequently, she has taken a pregnancy test too soon after taking a pregnancy test fertility drug that contains HCG. However, an ectopic pregnancy, menopause, or problems with ovaries also may contribute to misleading test results. These factors could restrain the growth of the global market during the forecast period.

OPPORTUNITY: Omicron, new variant of concern, offers growth opportunities for players in lateral flow assays market

Omicron is a new variant of concern of SARS-Cov-2, the virus responsible for COVID-19. It was first reported to the WHO from South Africa on November 24, 2021. On October 24, 2022, the WHO designated it as “Omicron,” a variant of concern specifically XBB and its sublineages (indicated as XBB*), as well as BQ.1 and its sublineages (indicated as BQ.1*). The level of variation has resulted in concerns regarding its transmissibility, defects in the immune system, and vaccine resistance. Many countries are preventing the spread of the Omicron variant by increasing the capacity of daily tests. Also, pharmaceutical and medical device companies are focusing on developing lateral flow assay kits for the detection of this new variant. Growth in the number of cases due to new variants such as Omicron will increase the demand for lateral flow assays kits.

CHALLENGE: Difficulties in procuring quality raw materials for development of lateral flow assays tests

The procurement and qualification of antigens and antibodies, also referred to as essential reagents, is one of the difficult tasks involved in developing lateral flow assay tests. The accuracy, specificity, stability, and reproducibility of the antibodies to be employed in tests must be evaluated because any impurity in the reagent could lead to the assay's failure. More than 1,000 data points must be examined and verified in order for a single lot of reagents to be qualified.

Kits & reagents segment accounted for the largest share in the lateral flow assay market.

The global market is segmented into kits & reagents and lateral flow readers. Kits & reagents accounted for the larger share of the global market. The large share of kits & reagents is due to the increasing the adoption of kits & reagents for infectious disease testing.

Food Safety & Environmental Testing segment is expected to witness the fastest growth, in global lateral flow assays market, during the forecast period.

The global market is segmented into clinical testing, veterinary diagnostics, food safety & environmental testing, and drug development & quality testing based on the application. The food safety & environmental testing segment is expected to witness the fastest growth during the forecast period. The fastest of this segment can be attributed to the available LFA tests for identifying toxins and other contaminants in the food industry can potentially compete with other immunoassay methods, such as immuno-chips and immuno-sensors and other analytical methods. The food & beverage industry is shifting from lab-based conventional microbiology techniques to rapid LFA tests for faster result generation

Competitive assays technique accounted for the second largest share of lateral flow assays market

The global market is segmented into competitive assays, sandwich assays, and multiplex detection assays. In competitive assay technique, the absence of color at the test line indicates the presence of analytes, while the appearance of color at both the test and control lines indicates a negative result.

Others samples accounted for the largest share of lateral flow assays market

The global market is segmented into blood, urine, saliva, and others samples. Others samples accounted for the largest market share. The global market for others samples is likely to be driven by increased R&D and the need for more specific and accurate disease testing. Nasal swabs, throat swabs, and vaginal fluid have been considered as other samples in the study.

The Diagnostics laboratories segment accounted for the third largest share of lateral flow assays market

Based on end users, the market is segmented into hospitals & clinics, diagnostic laboratories, home care settings, pharmaceutical & biotechnology companies, and other end users. The diagnostics laboratories segment accounted for the third largest market share The COVID-19 pandemic has resulted in an increased demand for rapid lateral flow-based diagnostic testing in laboratories. These tests may be conducted to gather data regarding the viral spread nationwide by government organizations and individuals for confirmation of symptomatic or asymptomatic cases with contact exposure.

North America accounted for the largest share of the lateral flow assays market

The market is sub-segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. North America accounted for the largest share of the lateral flow assay market, followed by Asia-Pacific, Europe, Latin America, and the Middle East & Africa. However, the APAC is expected to grow at the highest CAGR during the forecast period.

Geographic Snapshot: Lateral Flow Assays Market

Lateral Flow Assays Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The prominent players in the global lateral flow assays market include Abbott Laboratories (US), Quidel Corporation (US), F. Hoffman-La Roche AG (Switzerland), Danaher Corporation (US), Siemens AG (Germany), BD (US), bioMérieux SA (France), Thermo Fisher Scientific, Inc. (US), PerkinElmer Inc. (US), Hologic Inc. (US), QIAGEN N.V. (Netherlands), and Merck KGaA (Germany).

Lateral Flow Assays Market Report Scope

Report Metric

Details

Market Revenue in 2022

$20.5 billion

Projected Revenue by 2027

$22.6 billion

Revenue Rate

Poised to grow at a CAGR of 2.0%

Market Driver

Need for rapid diagnostics testing for COVID-19

Market Opportunity

Omicron, new variant of concern, offers growth opportunities for players

The research report categorizes Lateral Flow Assay Market to forecast revenue and analyze trends in each of the following submarkets:

By Type

  • Kits & Reagents
  • Lateral Flow Readers

By Application

  • Clinical Testing
  • Veterinary Diagnostics
  • Food Safety & Environmental Testing
  • Drug Development & Quality Testing

By Technique

  • Sandwich Assays
  • Competitive Assays
  • Multiplex Detection Assays

By Sample Type

  • Blood Samples
  • Urine Samples
  • Saliva Samples
  • Other Samples

By End User

  • Hospitals & Clinics
  • Diagnostics Laboratories
  • Home Care Settings
  • Pharmaceuticals & Biotechnology Companies
  • Other End User

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East and Africa

Recent Developments:

  • In October 2022, F. Hoffmann-La Roche Ltd. (Switzerland)  a next-generation portfolio of SARS-CoV-2 rapid antigen test 2.01, SARS-CoV-2 Rapid Antigen Test 2.0 Nasal2, and SARS-CoV-2 Rapid Antigen Test 2.0 Nasal3
  • In June 2021, Abbott Laboratories (US) received the CE approval for PanBio Rapid Antigen Self-test, opening access throughout Europe to fast, reliable COVID-19 testing

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 32)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
                    FIGURE 1 LATERAL FLOW ASSAYS MARKET SEGMENTATION
                    FIGURE 2 REGIONAL SCOPE
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED 
          TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
    1.5 STAKEHOLDERS 
    1.6 SUMMARY OF CHANGES 
           1.6.1 RECESSION IMPACT
 
2 RESEARCH METHODOLOGY (Page No. - 38)
    2.1 RESEARCH APPROACH 
          FIGURE 3 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    2.1.2.1 Primary sources
                    2.1.2.2 Key data from primary sources
                    2.1.2.3 Breakdown of primaries
                                FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2021)
          FIGURE 6 SUPPLY-SIDE ANALYSIS: LATERAL FLOW ASSAY MARKET (2021)
          FIGURE 7 APPROACH 3: DEMAND-SIDE APPROACH, BASED ON MALARIA LATERAL FLOW TESTING MARKET SIZE (2021)
          FIGURE 8 TOP-DOWN APPROACH
          FIGURE 9 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2022–2027): IMPACT ON MARKET GROWTH AND CAGR
          FIGURE 10 CAGR PROJECTIONS
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 11 DATA TRIANGULATION METHODOLOGY
    2.4 KEY INDUSTRY INSIGHTS 
    2.5 LIMITATIONS 
           2.5.1 METHODOLOGY-RELATED LIMITATIONS
    2.6 RISK ASSESSMENT 
    2.7 STUDY ASSUMPTIONS 
    2.8 RECESSION IMPACT 
 
3 EXECUTIVE SUMMARY (Page No. - 52)
    FIGURE 12 LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
    FIGURE 13 LATERAL FLOW ASSAY KITS AND REAGENTS MARKET, BY TECHNIQUE, 2022 VS. 2027 (USD MILLION)
    FIGURE 14 LATERAL FLOW ASSAY MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
    FIGURE 15 GLOBAL MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2022 VS. 2027 (USD MILLION)
    FIGURE 16 GLOBAL MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    FIGURE 17 GEOGRAPHIC SNAPSHOT OF GLOBAL MARKET
 
4 PREMIUM INSIGHTS (Page No. - 57)
    4.1 LATERAL FLOW ASSAYS MARKET OVERVIEW 
          FIGURE 18 HIGH PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
    4.2 REGIONAL MIX: LATERAL FLOW ASSAY MARKET 
          FIGURE 19 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
    4.3 ASIA PACIFIC: MARKET, BY APPLICATION AND COUNTRY (2021) 
          FIGURE 20 CLINICAL TESTING SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2021
    4.4 GLOBAL MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 21 CHINA TO REGISTER HIGHEST GROWTH IN FORECAST PERIOD
    4.5 GLOBAL MARKET: DEVELOPING VS. DEVELOPED COUNTRIES 
          FIGURE 22 DEVELOPING COUNTRIES TO OFFER HIGH GROWTH OPPORTUNITIES IN FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 61)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 23 LATERAL FLOW ASSAYS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 High prevalence of infectious diseases
                                TABLE 2 PREVALENCE OF HIV WORLDWIDE (2017 VS. 2021)
                    5.2.1.2 Rapidly increasing geriatric population
                                FIGURE 24 GERIATRIC POPULATION, BY REGION, 2020 VS. 2050 (MILLION)
                                FIGURE 25 GERIATRIC POPULATION, BY REGION, 2022 VS. 2030 VS. 2050 (% OF TOTAL POPULATION)
                    5.2.1.3 Growing use of home-based lateral flow assay devices
                    5.2.1.4 Growing demand for point-of-care testing
                    5.2.1.5 Need for rapid diagnostic testing for COVID-19
           5.2.2 RESTRAINTS
                    5.2.2.1 Inconsistent results of lateral flow assay tests
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Evolving applications of lateral flow assays
                                TABLE 3 LIST OF COMMERCIALLY AVAILABLE SALIVA LFA PRODUCTS
                    5.2.3.2 Rising demand for lateral flow assays in food & beverage industry
                    5.2.3.3 Omicron offers growth opportunities for players in lateral flow assay market
                                TABLE 4 EPIDEMIOLOGICAL UPDATE ON OMICRON VARIANT
                                TABLE 5 EXAMPLES OF LATERAL FLOW ASSAY KITS AVAILABLE FOR DETECTION OF OMICRON
           5.2.4 CHALLENGES
                    5.2.4.1 Limited reimbursements for lateral flow assay products
                    5.2.4.2 Difficulties in procuring quality raw materials for development of lateral flow assay tests
    5.3 COVID-19 IMPACT ASSESSMENT ON ECONOMIC SCENARIO 
    5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 
          FIGURE 26 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
    5.5 AVERAGE SELLING PRICE TREND 
           5.5.1 AVERAGE SELLING PRICES OF KEY PLAYERS, BY APPLICATION
                    TABLE 6 AVERAGE SELLING PRICE OF LATERAL FLOW ASSAYS (KITS AND REAGENTS)
           5.5.2 AVERAGE SELLING PRICE TRENDS
                    TABLE 7 AVERAGE SELLING PRICE OF LATERAL FLOW ANALYZERS, BY REGION, 2020 VS. 2021
    5.6 ECOSYSTEM MARKET MAP 
          FIGURE 27 GLOBAL MARKET: ECOSYSTEM ANALYSIS (2021)
    5.7 PATENT ANALYSIS 
           5.7.1 PATENT PUBLICATION TRENDS FOR LATERAL FLOW ASSAYS
                    FIGURE 28 GLOBAL PATENT PUBLICATION TRENDS IN GLOBAL MARKET, 2016–2022
           5.7.2 TOP APPLICANTS (COMPANIES) OF LATERAL FLOW ASSAY PATENTS
                    FIGURE 29 TOP COMPANIES THAT APPLIED FOR LATERAL FLOW ASSAY PATENTS, 2016–2022
           5.7.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN GLOBAL MARKET
                    FIGURE 30 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR LATERAL FLOW ASSAY PATENTS, 2016–2022
    5.8 VALUE CHAIN ANALYSIS 
          FIGURE 31 GLOBAL MARKET: VALUE CHAIN ANALYSIS (2021)
    5.9 TECHNOLOGY ANALYSIS 
           5.9.1 KEY TECHNOLOGY: LATERAL FLOW ASSAYS
           5.9.2 ADJACENT TECHNOLOGY: ENZYME-LINKED IMMUNOSORBENT ASSAYS
    5.10 CASE STUDY ANALYSIS 
    5.11 REGULATORY ANALYSIS 
           5.11.1 REGULATORY LANDSCAPE
                    5.11.1.1 North America
                    5.11.1.2 Europe
                    5.11.1.3 Asia
                               5.11.1.3.1 India
                               5.11.1.3.2 China
                               5.11.1.3.3 Japan
           5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 8 REGULATORY STANDARDS/APPROVALS REQUIRED FOR LATERAL FLOW IMMUNOASSAY BY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.12 PORTER’S FIVE FORCES ANALYSIS 
           TABLE 9 GLOBAL MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.12.1 THREAT OF NEW ENTRANTS
           5.12.2 THREAT OF SUBSTITUTES
           5.12.3 BARGAINING POWER OF SUPPLIERS
           5.12.4 BARGAINING POWER OF BUYERS
           5.12.5 INTENSITY OF COMPETITIVE RIVALRY
    5.13 ADJACENT MARKET ANALYSIS 
    5.14 KEY CONFERENCES AND EVENTS DURING 2023–2024 
            TABLE 10 GLOBAL MARKET: DETAILED LIST OF CONFERENCES & EVENTS
    5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE APPLICATIONS
                     TABLE 11 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE APPLICATIONS
           5.15.2 BUYING CRITERIA
                     FIGURE 33 KEY BUYING CRITERIA FOR TOP THREE APPLICATIONS
    5.16 TRADE ANALYSIS 
    5.17 INDUSTRY TRENDS 
           5.17.1 DETECTION OF HIV WITH LATERAL FLOW ASSAYS
                     TABLE 12 US: HIV PREVALENCE RATE, 2016–2020
           5.17.2 INCREASING ADOPTION OF QUANTITATIVE LATERAL FLOW ASSAYS DUE TO AVAILABILITY OF LFA READERS
    5.18 IMPACT OF INFLATION AND RECESSION ON GLOBAL MARKET 
 
6 LATERAL FLOW ASSAYS MARKET, BY PRODUCT (Page No. - 88)
    6.1 INTRODUCTION 
          TABLE 13 LATERAL FLOW ASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
    6.2 KITS AND REAGENTS 
           6.2.1 INCREASING DEMAND FOR POC TESTING TO DRIVE MARKET
                    TABLE 14 LATERAL FLOW KITS AND REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    6.3 LATERAL FLOW READERS 
          TABLE 15 EXAMPLES OF LATERAL FLOW READERS AVAILABLE IN MARKET
          TABLE 16 LATERAL FLOW ASSAY KITS AND REAGENTS WITH AND WITHOUT ANALYZERS
          TABLE 17 LATERAL FLOW READERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 18 LATERAL FLOW READERS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
          TABLE 19 LATERAL FLOW READERS MARKET, BY END USER, 2020–2027 (USD MILLION)
          TABLE 20 LATERAL FLOW READERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           6.3.1 DIGITAL/HANDHELD READERS
                    6.3.1.1 Technological advancements and high accuracy—major factors driving market
                                TABLE 21 DIGITAL/HANDHELD LATERAL FLOW READERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 22 DIGITAL/HANDHELD LATERAL FLOW READERS MARKET, BY REGION, 2020–2027 (THOUSAND UNITS)
           6.3.2 BENCHTOP READERS
                    6.3.2.1 Lower diagnosis cost per patient to drive adoption
                                TABLE 23 BENCHTOP LATERAL FLOW READERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 24 BENCHTOP LATERAL FLOW READERS MARKET, BY REGION, 2020–2027 (THOUSAND UNITS)
    6.4 INSIGHTS ON DISPOSABLE AND REUSABLE LATERAL FLOW READERS 
    6.5 LATERAL FLOW READERS MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE 
           6.5.1 PRODUCT PORTFOLIO ANALYSIS OF LATERAL FLOW READERS FOR CLINICAL DIAGNOSTIC APPLICATIONS
                    TABLE 25 PRODUCT PORTFOLIO ANALYSIS OF LATERAL FLOW READERS FOR CLINICAL DIAGNOSTIC APPLICATIONS
                    FIGURE 34 PRODUCT PORTFOLIO ANALYSIS OF LATERAL FLOW READERS FOR CLINICAL DIAGNOSTICS (2021)
 
7 LATERAL FLOW ASSAYS MARKET, BY APPLICATION (Page No. - 101)
    7.1 INTRODUCTION 
          TABLE 26 LATERAL FLOW ASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
    7.2 CLINICAL TESTING 
          TABLE 27 GLOBAL MARKET FOR CLINICAL TESTING, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 28 GLOBAL MARKET FOR CLINICAL TESTING, BY COUNTRY, 2020–2027 (USD MILLION)
           7.2.1 INFECTIOUS DISEASE TESTING
                    TABLE 29 GLOBAL MARKET FOR INFECTIOUS DISEASE TESTING, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 30 GLOBAL MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2020–2027 (USD MILLION)
                    7.2.1.1 Mosquito-borne diseases
                               7.2.1.1.1 Increasing incidence of dengue to support market growth
                                              TABLE 31 DENGUE TESTING PRODUCTS AVAILABLE IN MARKET
                                              TABLE 32 GLOBAL MARKET FOR MOSQUITO-BORNE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
                    7.2.1.2 COVID-19
                               7.2.1.2.1 COVID-19 pandemic resulted in adoption of rapid lateral flow tests
                                              TABLE 33 LATERAL FLOW ASSAY TESTS FOR COVID-19 (ANTIGEN AND ANTIBODY)
                                              TABLE 34 GLOBAL MARKET FOR COVID-19, BY COUNTRY, 2020–2027 (USD MILLION)
                    7.2.1.3 Influenza
                               7.2.1.3.1 Growing prevalence of influenza to support market growth
                                              TABLE 35 GLOBAL MARKET FOR INFLUENZA, BY COUNTRY, 2020–2027 (USD MILLION)
                    7.2.1.4 Sexually transmitted infections
                                TABLE 36 LATERAL FLOW ASSAY MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 37 GLOBAL MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                               7.2.1.4.1 HIV
                                             7.2.1.4.1.1 Growing awareness of HIV POC testing to drive market
                                                              TABLE 38 GLOBAL MARKET FOR HIV, BY COUNTRY, 2020–2027 (USD MILLION)
                               7.2.1.4.2 HPV
                                             7.2.1.4.2.1 Rising adoption of HPV testing to drive market during forecast period
                                                              TABLE 39 GLOBAL MARKET FOR HPV, BY COUNTRY, 2020–2027 (USD MILLION)
                               7.2.1.4.3 Chlamydia
                                             7.2.1.4.3.1 Growing incidence of chlamydia and rising awareness among patients to drive market
                                                              TABLE 40 GLOBAL MARKET FOR CHLAMYDIA, BY COUNTRY, 2020–2027 (USD MILLION)
                               7.2.1.4.4 Gonorrhea
                                             7.2.1.4.4.1 Rising incidence of gonorrhea and increased funding for R&D to support market growth
                                                              TABLE 41 GLOBAL MARKET FOR GONORRHEA, BY COUNTRY, 2020–2027 (USD MILLION)
                               7.2.1.4.5 Syphilis
                                             7.2.1.4.5.1 Growing adoption of novel technologies to support market growth
                                                              TABLE 42 GLOBAL MARKET FOR SYPHILIS, BY COUNTRY, 2020–2027 (USD MILLION)
                               7.2.1.4.6 Other sexually transmitted infections
                                              TABLE 43 GLOBAL MARKET FOR OTHER SEXUALLY TRANSMITTED INFECTIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    7.2.1.5 Hepatitis
                               7.2.1.5.1 Nucleic acid hybridization-based lateral flow assays hold great potential in hepatitis testing market
                                              TABLE 44 GLOBAL MARKET FOR HEPATITIS, BY COUNTRY, 2020–2027 (USD MILLION)
                    7.2.1.6 Tuberculosis
                               7.2.1.6.1 Rising prevalence and growing focus on early diagnosis and treatment to drive market
                                              TABLE 45 LATERAL FLOW ASSAY MARKET FOR TUBERCULOSIS, BY COUNTRY, 2020–2027 (USD MILLION)
                    7.2.1.7 Other infectious diseases
                               TABLE 46 GLOBAL MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
           7.2.2 CARDIAC MARKER TESTING
                    TABLE 47 GLOBAL MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 48 LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY COUNTRY, 2020–2027 (USD MILLION)
                    7.2.2.1 Troponin I and T
                               7.2.2.1.1 Introduction of high-sensitivity troponin assays to drive market
                                              TABLE 49 GLOBAL MARKET FOR TROPONIN I AND T TESTING, BY COUNTRY, 2020–2027 (USD MILLION)
                    7.2.2.2 CK-MB
                               7.2.2.2.1 Growing applications of lateral flow tests in acute myocardial injuries to drive market
                                              TABLE 50 GLOBAL MARKET FOR CK-MB TESTING, BY COUNTRY, 2020–2027 (USD MILLION)
                    7.2.2.3 BNP and NT-proBNP
                               7.2.2.3.1 Increasing demand for cardiac biomarker tests to detect heart stress and damage to propel adoption
                                              TABLE 51 GLOBAL MARKET FOR BNP AND NT-PROBNP TESTING, BY COUNTRY, 2020–2027 (USD MILLION)
                    7.2.2.4 Myoglobin
                               7.2.2.4.1 Availability of new high-sensitivity cardiac troponin assays to restrict market growth
                                              TABLE 52 GLOBAL MARKET FOR MYOGLOBIN TESTING, BY COUNTRY, 2020–2027 (USD MILLION)
                    7.2.2.5 D-dimer
                               7.2.2.5.1 Rising incidence of cardiovascular diseases to drive market for D-dimer tests
                                              TABLE 53 GLOBAL MARKET FOR D-DIMER TESTING, BY COUNTRY, 2020–2027 (USD MILLION)
                    7.2.2.6 Other cardiac markers
                                TABLE 54 GLOBAL MARKET FOR OTHER CARDIAC MARKER TESTS, BY COUNTRY, 2020–2027 (USD MILLION)
           7.2.3 PREGNANCY AND FERTILITY TESTING
                    TABLE 55 GLOBAL MARKET FOR PREGNANCY AND FERTILITY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 56 GLOBAL MARKET FOR PREGNANCY AND FERTILITY TESTING, BY COUNTRY, 2020–2027 (USD MILLION)
                    7.2.3.1 Pregnancy testing
                               7.2.3.1.1 Most common application area for lateral flow assays
                                              TABLE 57 GLOBAL MARKET FOR PREGNANCY TESTING, BY COUNTRY, 2020–2027 (USD MILLION)
                    7.2.3.2 Fertility testing
                               7.2.3.2.1 Rising infertility rates to drive demand for POC fertility testing kits
                                              TABLE 58 LATERAL FLOW ASSAY MARKET FOR FERTILITY TESTING, BY COUNTRY, 2020–2027 (USD MILLION)
           7.2.4 CHOLESTEROL/LIPID TESTING
                    7.2.4.1 Growing prevalence of obesity and CVD to drive market
                                TABLE 59 GLOBAL MARKET FOR CHOLESTEROL/LIPID TESTING, BY COUNTRY, 2020–2027 (USD MILLION)
           7.2.5 DRUGS-OF-ABUSE TESTING
                    7.2.5.1 Technological advancements and growing focus on workplace drug testing to drive market
                                TABLE 60 GLOBAL MARKET FOR DRUGS-OF-ABUSE TESTING, BY COUNTRY, 2020–2027 (USD MILLION)
           7.2.6 OTHER CLINICAL TESTS
                    TABLE 61 GLOBAL MARKET FOR OTHER CLINICAL TESTS, BY COUNTRY, 2020–2027 (USD MILLION)
    7.3 VETERINARY DIAGNOSTICS 
           7.3.1 INFECTIOUS DISEASE OUTBREAKS, PARTICULARLY IN LARGE LIVESTOCK ANIMALS, TO DRIVE MARKET
                    TABLE 62 GLOBAL MARKET FOR VETERINARY DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
    7.4 FOOD SAFETY AND ENVIRONMENTAL TESTING 
           7.4.1 HIGH SENSITIVITY AND EASE OF USE SUPPORTING MARKET GROWTH
                    TABLE 63 GLOBAL MARKET FOR FOOD SAFETY AND ENVIRONMENTAL TESTING, BY COUNTRY, 2020–2027 (USD MILLION)
    7.5 DRUG DEVELOPMENT AND QUALITY TESTING 
           7.5.1 INCREASING FOCUS ON PRODUCT SAFETY AND QUALITY ASSURANCE TO DRIVE MARKET
                    TABLE 64 GLOBAL MARKET FOR DRUG DEVELOPMENT AND QUALITY TESTING, BY COUNTRY, 2020–2027 (USD MILLION)
 
8 LATERAL FLOW ASSAYS MARKET, BY TECHNIQUE (Page No. - 145)
    8.1 INTRODUCTION 
          TABLE 65 LATERAL FLOW ASSAY KITS AND REAGENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
          TABLE 66 LATERAL FLOW ASSAY KITS AND REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    8.2 SANDWICH ASSAYS 
           8.2.1 WIDE APPLICATIONS IN CLINICAL TESTING TO SUPPORT MARKET GROWTH
                    TABLE 67 LATERAL FLOW SANDWICH ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    8.3 COMPETITIVE ASSAYS 
           8.3.1 REDUCED SELECTIVITY AND SENSITIVITY IN RELATION TO SANDWICH ASSAYS TO HAMPER GROWTH
                    TABLE 68 LATERAL FLOW COMPETITIVE ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    8.4 MULTIPLEX DETECTION ASSAYS 
           8.4.1 INCREASING ADOPTION OF MULTI-ANALYTE ASSAYS AMONG CLINICIANS TO DRIVE MARKET
                    TABLE 69 LATERAL FLOW MULTIPLEX DETECTION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
 
9 LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE (Page No. - 152)
    9.1 INTRODUCTION 
          TABLE 70 LATERAL FLOW ASSAY MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
    9.2 BLOOD SAMPLES 
           9.2.1 INCREASING USE OF BLOOD SAMPLES IN INFECTIOUS DISEASE TESTING TO DRIVE MARKET
                    TABLE 71 GLOBAL MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2020–2027 (USD MILLION)
    9.3 URINE SAMPLES 
           9.3.1 GROWING USE OF URINE SAMPLES IN PREGNANCY AND DRUGS-OF-ABUSE TESTING TO DRIVE MARKET
                    TABLE 72 GLOBAL MARKET FOR URINE SAMPLES, BY COUNTRY, 2020–2027 (USD MILLION)
    9.4 SALIVA SAMPLES 
           9.4.1 EASY AND LOW-COST COLLECTION, TRANSPORT, AND ANALYSIS OF SALIVA SAMPLES TO SUPPORT ADOPTION
                    TABLE 73 GLOBAL MARKET FOR SALIVA SAMPLES, BY COUNTRY, 2020–2027 (USD MILLION)
    9.5 OTHER SAMPLES 
          TABLE 74 GLOBAL MARKET FOR OTHER SAMPLES, BY COUNTRY, 2020–2027 (USD MILLION)
 
10 LATERAL FLOW ASSAYS MARKET, BY END USER (Page No. - 158)
     10.1 INTRODUCTION 
             TABLE 75 LATERAL FLOW ASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)
     10.2 HOSPITALS AND CLINICS 
             10.2.1 INCREASING USE OF POC TESTS TO DRIVE MARKET
                        TABLE 76 GLOBAL MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2020–2027 (USD MILLION)
     10.3 HOME CARE SETTINGS 
             10.3.1 GROWING ACCEPTANCE OF REMOTE MONITORING TO PROPEL MARKET
                        TABLE 77 GLOBAL MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2020–2027 (USD MILLION)
     10.4 DIAGNOSTIC LABORATORIES 
             10.4.1 HIGH PREFERENCE FOR LABORATORY TESTING TO TEST URINE AND BLOOD SAMPLES TO SUPPORT MARKET GROWTH
                        TABLE 78 GLOBAL MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
     10.5 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 
             10.5.1 INCREASING FOCUS ON PRODUCT SAFETY TO DRIVE ADOPTION OF LATERAL FLOW ASSAYS
                        TABLE 79 GLOBAL MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
     10.6 OTHER END USERS 
             TABLE 80 GLOBAL MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION)
 
11 LATERAL FLOW ASSAYS MARKET, BY REGION (Page No. - 166)
     11.1 INTRODUCTION 
             FIGURE 35 CHINA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
             TABLE 81 LATERAL FLOW ASSAY MARKET, BY REGION, 2020–2027 (USD MILLION)
     11.2 NORTH AMERICA 
             TABLE 82 NORTH AMERICA: MACROECONOMIC INDICATORS
             FIGURE 36 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET SNAPSHOT
             TABLE 83 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 84 NORTH AMERICA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             TABLE 85 NORTH AMERICA: LATERAL FLOW READERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 86 NORTH AMERICA: LATERAL FLOW ASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
             TABLE 87 NORTH AMERICA: MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 88 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASE TESTING, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 89 NORTH AMERICA: MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 90 NORTH AMERICA: MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 91 NORTH AMERICA: MARKET FOR PREGNANCY AND FERTILITY TESTING, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 92 NORTH AMERICA: LATERAL FLOW ASSAY KITS AND REAGENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
             TABLE 93 NORTH AMERICA: MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
             TABLE 94 NORTH AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.2.1 US
                        11.2.1.1 Largest market for lateral flow assays
                                      TABLE 95 US: MACROECONOMIC INDICATORS
                                      TABLE 96 US: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 97 US: LATERAL FLOW READERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 98 US: LATERAL FLOW ASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 99 US: MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 100 US: MARKET FOR INFECTIOUS DISEASE TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 101 US: MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 102 US: MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 103 US: MARKET FOR PREGNANCY AND FERTILITY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 104 US: LATERAL FLOW ASSAY KITS AND REAGENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
                                      TABLE 105 US: MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
                                      TABLE 106 US: MARKET, BY END USER, 2020–2027 USD MILLION)
             11.2.2 CANADA
                        11.2.2.1 Availability of research funding and implementation of favorable government initiatives to drive market
                                      TABLE 107 CANADA: MACROECONOMIC INDICATORS
                                      TABLE 108 CANADA: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 109 CANADA: LATERAL FLOW READERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 110 CANADA: LATERAL FLOW ASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 111 CANADA: MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 112 CANADA: MARKET FOR INFECTIOUS DISEASE TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 113 CANADA: MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 114 CANADA: MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 115 CANADA: MARKET FOR PREGNANCY AND FERTILITY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 116 CANADA: LATERAL FLOW ASSAY KITS AND REAGENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
                                      TABLE 117 CANADA: MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
                                      TABLE 118 CANADA: MARKET, BY END USER, 2020–2027 USD MILLION)
             11.2.3 RECESSION IMPACT
     11.3 EUROPE 
             TABLE 119 EUROPE: LATERAL FLOW ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 120 EUROPE: LATERAL FLOW ASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             TABLE 121 EUROPE: LATERAL FLOW READERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 122 EUROPE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
             TABLE 123 EUROPE: MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 124 EUROPE: MARKET FOR INFECTIOUS DISEASE TESTING, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 125 EUROPE: MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 126 EUROPE: MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 127 EUROPE: MARKET FOR PREGNANCY AND FERTILITY TESTING, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 128 EUROPE: LATERAL FLOW ASSAY KITS AND REAGENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
             TABLE 129 EUROPE: MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
             TABLE 130 EUROPE: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.3.1 GERMANY
                        11.3.1.1 Growing number of POC diagnostic centers to drive demand for lateral flow assays
                                      TABLE 131 GERMANY: MACROECONOMIC INDICATORS
                                      TABLE 132 GERMANY: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 133 GERMANY: LATERAL FLOW READERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 134 GERMANY: LATERAL FLOW ASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 135 GERMANY: MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 136 GERMANY: MARKET FOR INFECTIOUS DISEASE TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 137 GERMANY: MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 138 GERMANY: MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 139 GERMANY: MARKET FOR PREGNANCY AND FERTILITY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 140 GERMANY: LATERAL FLOW ASSAY KITS AND REAGENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
                                      TABLE 141 GERMANY: MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
                                      TABLE 142 GERMANY: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.3.2 FRANCE
                        11.3.2.1 High prevalence of age-related chronic and infectious diseases to drive market
                                      TABLE 143 FRANCE: MACROECONOMIC INDICATORS
                                      TABLE 144 FRANCE: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 145 FRANCE: LATERAL FLOW READERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 146 FRANCE: LATERAL FLOW ASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 147 FRANCE: MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 148 FRANCE: MARKET FOR INFECTIOUS DISEASE TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 149 FRANCE: MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 150 FRANCE: MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 151 FRANCE: MARKET FOR PREGNANCY AND FERTILITY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 152 FRANCE: LATERAL FLOW ASSAY KITS AND REAGENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
                                      TABLE 153 FRANCE: MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
                                      TABLE 154 FRANCE: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.3.3 UK
                        11.3.3.1 Rising prevalence of obesity to propel market
                                      TABLE 155 UK: MACROECONOMIC INDICATORS
                                      TABLE 156 UK: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 157 UK: LATERAL FLOW READERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 158 UK: LATERAL FLOW ASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 159 UK: MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 160 UK: MARKET FOR INFECTIOUS DISEASE TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 161 UK: MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 162 UK: MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 163 UK: MARKET FOR PREGNANCY AND FERTILITY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 164 UK: LATERAL FLOW ASSAY KITS AND REAGENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
                                      TABLE 165 UK: MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
                                      TABLE 166 UK: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.3.4 ITALY
                        11.3.4.1 Growing initiatives toward decentralization of medical services to support market growth
                                      TABLE 167 ITALY: MACROECONOMIC INDICATORS
                                      TABLE 168 ITALY: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 169 ITALY: LATERAL FLOW READERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 170 ITALY: LATERAL FLOW ASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 171 ITALY: MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 172 ITALY: MARKET FOR INFECTIOUS DISEASE TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 173 ITALY: MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 174 ITALY: MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 175 ITALY: MARKET FOR PREGNANCY AND FERTILITY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 176 ITALY: LATERAL FLOW ASSAY KITS AND REAGENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
                                      TABLE 177 ITALY: MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
                                      TABLE 178 ITALY: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.3.5 SPAIN
                        11.3.5.1 Increasing focus of international organizations and domestic players on development of POC products to aid market growth
                                      TABLE 179 SPAIN: MACROECONOMIC INDICATORS
                                      TABLE 180 SPAIN: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 181 SPAIN: LATERAL FLOW READERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 182 SPAIN: LATERAL FLOW ASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 183 SPAIN: MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 184 SPAIN: MARKET FOR INFECTIOUS DISEASE TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 185 SPAIN: MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 186 SPAIN: MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 187 SPAIN: MARKET FOR PREGNANCY AND FERTILITY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 188 SPAIN: LATERAL FLOW ASSAY KITS AND REAGENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
                                      TABLE 189 SPAIN: MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
                                      TABLE 190 SPAIN: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.3.6 REST OF EUROPE
                        TABLE 191 REST OF EUROPE: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 192 REST OF EUROPE: LATERAL FLOW READERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 193 REST OF EUROPE: LATERAL FLOW ASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 194 REST OF EUROPE: MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 195 REST OF EUROPE: MARKET FOR INFECTIOUS DISEASE TESTING, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 196 REST OF EUROPE: MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 197 REST OF EUROPE: MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 198 REST OF EUROPE: MARKET FOR PREGNANCY AND FERTILITY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 199 REST OF EUROPE: LATERAL FLOW ASSAY KITS AND REAGENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
                        TABLE 200 REST OF EUROPE: MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
                        TABLE 201 REST OF EUROPE: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.3.7 RECESSION IMPACT
     11.4 ASIA PACIFIC 
             FIGURE 37 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET SNAPSHOT
             TABLE 202 ASIA PACIFIC: LATERAL FLOW ASSAY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 203 ASIA PACIFIC: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             TABLE 204 ASIA PACIFIC: LATERAL FLOW READERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 205 ASIA PACIFIC: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
             TABLE 206 ASIA PACIFIC: MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 207 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASE TESTING, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 208 ASIA PACIFIC: MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 209 ASIA PACIFIC: MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 210 ASIA PACIFIC: MARKET FOR PREGNANCY AND FERTILITY TESTING, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 211 ASIA PACIFIC: LATERAL FLOW ASSAY KITS AND REAGENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
             TABLE 212 ASIA PACIFIC: MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
             TABLE 213 ASIA PACIFIC: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.4.1 CHINA
                        11.4.1.1 Growing adoption of lateral flow assays in veterinary diagnostics and drug development to drive market
                                      TABLE 214 CHINA: MACROECONOMIC INDICATORS
                                      TABLE 215 CHINA: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 216 CHINA: LATERAL FLOW READERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 217 CHINA: LATERAL FLOW ASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 218 CHINA: MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 219 CHINA: MARKET FOR INFECTIOUS DISEASE TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 220 CHINA: MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 221 CHINA: MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 222 CHINA: MARKET FOR PREGNANCY AND FERTILITY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 223 CHINA: LATERAL FLOW ASSAY KITS AND REAGENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
                                      TABLE 224 CHINA: MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
                                      TABLE 225 CHINA: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.4.2 JAPAN
                        11.4.2.1 Increasing prevalence of age-related illnesses to drive market
                                      TABLE 226 JAPAN: MACROECONOMIC INDICATORS
                                      TABLE 227 JAPAN: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 228 JAPAN: LATERAL FLOW READERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 229 JAPAN: LATERAL FLOW ASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 230 JAPAN: MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 231 JAPAN: MARKET FOR INFECTIOUS DISEASE TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 232 JAPAN: MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 233 JAPAN: MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 234 JAPAN: MARKET FOR PREGNANCY AND FERTILITY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 235 JAPAN: LATERAL FLOW ASSAY KITS AND REAGENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
                                      TABLE 236 JAPAN: MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
                                      TABLE 237 JAPAN: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.4.3 INDIA
                        11.4.3.1 Growing healthcare concerns and rising income levels to propel market
                                      TABLE 238 INDIA: MACROECONOMIC INDICATORS
                                      TABLE 239 INDIA: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 240 INDIA: LATERAL FLOW READERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 241 INDIA: LATERAL FLOW ASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 242 INDIA: MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 243 INDIA: MARKET FOR INFECTIOUS DISEASE TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 244 INDIA: MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 245 INDIA: MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 246 INDIA: MARKET FOR PREGNANCY AND FERTILITY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 247 INDIA: LATERAL FLOW ASSAY KITS AND REAGENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
                                      TABLE 248 INDIA: MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
                                      TABLE 249 INDIA: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.4.4 AUSTRALIA
                        11.4.4.1 Increasing prevalence of infectious diseases, especially influenza, to drive market
                                      TABLE 250 AUSTRALIA: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 251 AUSTRALIA: LATERAL FLOW READERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 252 AUSTRALIA: LATERAL FLOW ASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 253 AUSTRALIA: MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 254 AUSTRALIA: MARKET FOR INFECTIOUS DISEASE TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 255 AUSTRALIA: MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 256 AUSTRALIA: MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 257 AUSTRALIA: MARKET FOR PREGNANCY AND FERTILITY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 258 AUSTRALIA: LATERAL FLOW ASSAY KITS AND REAGENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
                                      TABLE 259 AUSTRALIA: MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
                                      TABLE 260 AUSTRALIA: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.4.5 REST OF ASIA PACIFIC
                        TABLE 261 REST OF ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 262 REST OF ASIA PACIFIC: LATERAL FLOW READERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 263 REST OF ASIA PACIFIC: LATERAL FLOW ASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 264 REST OF ASIA PACIFIC: MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 265 REST OF ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASE TESTING, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 266 REST OF ASIA PACIFIC: MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 267 REST OF ASIA PACIFIC: MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 268 REST OF ASIA PACIFIC: MARKET FOR PREGNANCY AND FERTILITY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 269 REST OF ASIA PACIFIC: LATERAL FLOW ASSAY KITS AND REAGENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
                        TABLE 270 REST OF ASIA PACIFIC: MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
                        TABLE 271 REST OF ASIA PACIFIC: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.4.6 RECESSION IMPACT
     11.5 LATIN AMERICA 
             TABLE 272 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 273 LATIN AMERICA: LATERAL FLOW ASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             TABLE 274 LATIN AMERICA: LATERAL FLOW READERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 275 LATIN AMERICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
             TABLE 276 LATIN AMERICA: MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 277 LATIN AMERICA: MARKET FOR INFECTIOUS DISEASE TESTING, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 278 LATIN AMERICA: MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 279 LATIN AMERICA: MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 280 LATIN AMERICA: MARKET FOR PREGNANCY AND FERTILITY TESTING, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 281 LATIN AMERICA: LATERAL FLOW ASSAY KITS AND REAGENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
             TABLE 282 LATIN AMERICA: MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
             TABLE 283 LATIN AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.5.1 BRAZIL
                        11.5.1.1 High healthcare expenditure and increasing geriatric population to drive market
                                      TABLE 284 BRAZIL: MACROECONOMIC INDICATORS
                                      TABLE 285 BRAZIL: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 286 BRAZIL: LATERAL FLOW READERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 287 BRAZIL: LATERAL FLOW ASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 288 BRAZIL: MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 289 BRAZIL: MARKET FOR INFECTIOUS DISEASE TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 290 BRAZIL: MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 291 BRAZIL: MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 292 BRAZIL: MARKET FOR PREGNANCY AND FERTILITY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 293 BRAZIL: LATERAL FLOW ASSAY KITS AND REAGENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
                                      TABLE 294 BRAZIL: MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
                                      TABLE 295 BRAZIL: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.5.2 MEXICO
                        11.5.2.1 High prevalence of obesity and related chronic diseases to propel market
                                      TABLE 296 MEXICO: MACROECONOMIC INDICATORS
                                      TABLE 297 MEXICO: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 298 MEXICO: LATERAL FLOW READERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 299 MEXICO: LATERAL FLOW ASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 300 MEXICO: MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 301 MEXICO: MARKET FOR INFECTIOUS DISEASE TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 302 MEXICO: MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 303 MEXICO: MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 304 MEXICO: MARKET FOR PREGNANCY AND FERTILITY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 305 MEXICO: LATERAL FLOW ASSAY KITS AND REAGENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
                                      TABLE 306 MEXICO: MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
                                      TABLE 307 MEXICO: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.5.3 REST OF LATIN AMERICA
                        TABLE 308 REST OF LATIN AMERICA: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 309 REST OF LATIN AMERICA: LATERAL FLOW READERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 310 REST OF LATIN AMERICA: LATERAL FLOW ASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 311 REST OF LATIN AMERICA: MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 312 REST OF LATIN AMERICA: MARKET FOR INFECTIOUS DISEASE TESTING, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 313 REST OF LATIN AMERICA: MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 314 REST OF LATIN AMERICA: MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 315 REST OF LATIN AMERICA: MARKET FOR PREGNANCY AND FERTILITY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 316 REST OF LATIN AMERICA: LATERAL FLOW ASSAY KITS AND REAGENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
                        TABLE 317 REST OF LATIN AMERICA: MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
                        TABLE 318 REST OF LATIN AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.5.4 RECESSION IMPACT
     11.6 MIDDLE EAST & AFRICA 
             11.6.1 SIGNIFICANT SUPPORT FROM GOVERNMENTS AND GLOBAL FIRMS TOWARD EXPANSION OF HEALTHCARE SERVICES TO DRIVE MARKET
                        TABLE 319 AFRICA: MACROECONOMIC INDICATORS
                        TABLE 320 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 321 MIDDLE EAST & AFRICA: LATERAL FLOW READERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 322 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 323 MIDDLE EAST & AFRICA: MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 324 MIDDLE EAST & AFRICA: MARKET FOR INFECTIOUS DISEASE TESTING, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 325 MIDDLE EAST & AFRICA: MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 326 MIDDLE EAST & AFRICA: MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 327 MIDDLE EAST & AFRICA: MARKET FOR PREGNANCY AND FERTILITY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 328 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY KITS AND REAGENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
                        TABLE 329 MIDDLE EAST & AFRICA: MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
                        TABLE 330 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.6.2 RECESSION IMPACT
 
12 COMPETITIVE LANDSCAPE (Page No. - 278)
     12.1 OVERVIEW 
     12.2 STRATEGIES ADOPTED BY KEY PLAYERS 
             FIGURE 38 OVERVIEW OF STRATEGIES ADOPTED BY MAJOR PLAYERS IN LATERAL FLOW ASSAYS MARKET
     12.3 REVENUE SHARE ANALYSIS OF KEY PLAYERS IN GLOBAL MARKET 
     12.4 MARKET SHARE ANALYSIS 
             FIGURE 40 LATERAL FLOW ASSAY MARKET SHARE ANALYSIS, BY KEY PLAYER (2021)
     12.5 R&D ASSESSMENT OF KEY PLAYERS 
             FIGURE 41 R&D EXPENDITURE: MAJOR PLAYERS IN GLOBAL MARKET, 2020 VS. 2021
     12.6 COMPANY EVALUATION QUADRANT FOR KEY PLAYERS 
             12.6.1 STARS
             12.6.2 PERVASIVE PLAYERS
             12.6.3 EMERGING LEADERS
             12.6.4 PARTICIPANTS
                        FIGURE 42 GLOBAL MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2021
     12.7 COMPANY EVALUATION QUADRANT FOR SMES AND STARTUPS 
             12.7.1 PROGRESSIVE COMPANIES
             12.7.2 DYNAMIC COMPANIES
             12.7.3 STARTING BLOCKS
             12.7.4 RESPONSIVE COMPANIES
                        FIGURE 43 GLOBAL MARKET: COMPANY EVALUATION MATRIX FOR SMES AND STARTUPS, 2021
     12.8 COMPETITIVE BENCHMARKING 
             12.8.1 COMPANY FOOTPRINT ANALYSIS
                        TABLE 332 OVERALL COMPANY FOOTPRINT ANALYSIS (25 COMPANIES)
                        TABLE 333 PRODUCT FOOTPRINT ANALYSIS (25 COMPANIES)
                        TABLE 334 TECHNIQUE FOOTPRINT ANALYSIS (25 COMPANIES)
                        TABLE 335 APPLICATION FOOTPRINT ANALYSIS (25 COMPANIES)
                        TABLE 336 SAMPLE TYPE FOOTPRINT ANALYSIS (25 COMPANIES)
                        TABLE 337 END-USER FOOTPRINT ANALYSIS (25 COMPANIES)
                        TABLE 338 REGIONAL FOOTPRINT ANALYSIS (25 COMPANIES)
     12.9 COMPETITIVE SCENARIO 
             12.9.1 PRODUCT LAUNCHES AND APPROVALS
                        TABLE 339 PRODUCT LAUNCHES AND APPROVALS, JANUARY 2019–DECEMBER 2022
             12.9.2 DEALS
                        TABLE 340 DEALS, JANUARY 2019–DECEMBER 2022
             12.9.3 OTHER DEVELOPMENTS
                        TABLE 341 OTHER DEVELOPMENTS, JANUARY 2019–DECEMBER 2022
 
13 COMPANY PROFILES (Page No. - 298)
(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*
     13.1 KEY PLAYERS 
             13.1.1 ABBOTT LABORATORIES
                        TABLE 342 ABBOTT LABORATORIES: BUSINESS OVERVIEW
                        FIGURE 44 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
             13.1.2 F. HOFFMANN-LA ROCHE LTD.
                        TABLE 343 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
                        FIGURE 45 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2021)
             13.1.3 QUIDEL CORPORATION
                        TABLE 344 QUIDEL CORPORATION: BUSINESS OVERVIEW
                        FIGURE 46 QUIDEL CORPORATION: COMPANY SNAPSHOT (2021)
             13.1.4 DANAHER CORPORATION
                        TABLE 345 DANAHER CORPORATION: BUSINESS OVERVIEW
                        FIGURE 47 DANAHER CORPORATION: COMPANY SNAPSHOT (2021)
             13.1.5 SIEMENS AG
                        TABLE 346 SIEMENS AG: BUSINESS OVERVIEW
                        FIGURE 48 SIEMENS AG: COMPANY SNAPSHOT (2021)
             13.1.6 BECTON, DICKINSON AND COMPANY
                        TABLE 347 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
                        FIGURE 49 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)
             13.1.7 BIOMÉRIEUX SA
                        TABLE 348 BIOMÉRIEUX SA: BUSINESS OVERVIEW
                        FIGURE 50 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2021)
             13.1.8 THERMO FISHER SCIENTIFIC INC.
                        TABLE 349 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
                        FIGURE 51 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
             13.1.9 PERKINELMER INC.
                        TABLE 350 PERKINELMER INC.: BUSINESS OVERVIEW
                        FIGURE 52 PERKINELMER INC.: COMPANY SNAPSHOT (2021)
             13.1.10 QIAGEN N.V.
                        TABLE 351 QIAGEN N. V.: BUSINESS OVERVIEW
                        FIGURE 53 QIAGEN N. V.: COMPANY SNAPSHOT (2021)
     13.2 OTHER PLAYERS 
             13.2.1 MERCK KGAA
                        TABLE 352 MERCK KGAA: BUSINESS OVERVIEW
                        FIGURE 54 MERCK KGAA: COMPANY SNAPSHOT (2021)
             13.2.2 HOLOGIC, INC.
                        TABLE 353 HOLOGIC, INC.: BUSINESS OVERVIEW
                        FIGURE 55 HOLOGIC, INC.: COMPANY SNAPSHOT (2021)
             13.2.3 ABCAM PLC
                        TABLE 354 ABCAM PLC: BUSINESS OVERVIEW
                        FIGURE 56 ABCAM PLC: COMPANY SNAPSHOT (2021)
             13.2.4 SURMODICS, INC.
                        TABLE 355 SURMODICS, INC.: BUSINESS OVERVIEW
                        FIGURE 57 SURMODICS, INC.: COMPANY SNAPSHOT (2021)
             13.2.5 CHEMBIO DIAGNOSTICS, INC.
                        TABLE 356 CHEMBIO DIAGNOSTICS, INC.: BUSINESS OVERVIEW
                        FIGURE 58 CHEMBIO DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2021)
             13.2.6 ORASURE TECHNOLOGIES
                        TABLE 357 ORASURE TECHNOLOGIES: BUSINESS OVERVIEW
                        FIGURE 59 ORASURE TECHNOLOGIES: COMPANY SNAPSHOT (2021)
             13.2.7 DCN DIAGNOSTICS
                        TABLE 358 DCN DIAGNOSTICS: BUSINESS OVERVIEW
             13.2.8 POLYSCIENCES INC.
                        TABLE 359 POLYSCIENCES INC.: BUSINESS OVERVIEW
             13.2.9 ABINGDON HEALTH
                        TABLE 360 ABINGDON HEALTH: BUSINESS OVERVIEW
             13.2.10 ORANOXIS INC.
                        TABLE 361 ORANOXIS INC.: BUSINESS OVERVIEW
             13.2.11 AESKU.GROUP GMBH
                        TABLE 362 AESKU.GROUP GMBH: BUSINESS OVERVIEW
             13.2.12 BIO GROUP MEDICAL SYSTEM S.R.L
                        TABLE 363 BIO GROUP MEDICAL SYSTEM S.R.L: BUSINESS OVERVIEW
             13.2.13 PHARMACT GMBH
                        TABLE 364 PHARMACT GMBH: BUSINESS OVERVIEW
             13.2.14 DIESSE DIAGNOSTICA SENESE S.P.A.
                        TABLE 365 DIESSE DIAGNOSTICA SENESE S.P.A.: BUSINESS OVERVIEW
             13.2.15 XIAMEN BIOTIME BIOTECHNOLOGY CO., LTD.
                        TABLE 366 XIAMEN BIOTIME BIOTECHNOLOGY CO., LTD.: BUSINESS OVERVIEW
 
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.
 
14 APPENDIX (Page No. - 366)
     14.1 DISCUSSION GUIDE 
     14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     14.3 CUSTOMIZATION OPTIONS 
     14.4 RELATED REPORTS 
     14.5 AUTHOR DETAILS 

This study involved four major approaches in estimating the current lateral flow assays market size. Extensive research was conducted to collect information on the market as well as its peer and parent markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the value market. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

This research study involved widespread secondary sources; directories; databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the global market. It was also used to obtain important information about key players, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the global market. Primary sources from the demand side include personnel from hospitals, diagnostic labs, pharma companies, and food & beverage companies.

Market Size Estimation

The total size of the lateral flow assays market was arrived at after data triangulation from four different approaches, as mentioned below.

Bottom-up Approach: Revenues of individual companies were gathered from public sources and databases. Shares of the lateral flow assays businesses of leading players were gathered from secondary sources to the extent available. In certain cases, the share of the business unit was ascertained after a detailed analysis of various parameters, including product portfolio, market positioning, selling price, and geographic reach and strength. Individual shares or revenue estimates were validated through expert interviews.

Country level Analysis: The size of the global market was obtained from the annual presentations of leading players and secondary data available in the public domain. The share of kits & reagents in the overall lateral flow assay market was obtained from secondary data and validated by primary participants to arrive at the total market. Primary participants further validated the numbers.

Primary Interviews: As a part of the primary research process, individual respondent insights on the market size and growth were taken during the interview (regional and global, as applicable). All the responses were collated, and a weighted average was taken to derive a probabilistic estimate of the market size and growth rate.

Geographic market assessment (by region & country): The geographic assessment was done using the following approaches:

Approach 1: Geographic revenue contributions/splits of leading players in the market (wherever available) and respective growth trends

Approach 2: Geographic adoption trends for individual product segments by end users and growth prospects for each of the segments (assumptions and indicative estimates validated from primary interviews)

At each point, the assumptions and approaches were validated through industry experts contacted during primary research. Considering the limitations of data available from secondary research, revenue estimates for individual companies (for the overall lateral flow assays market and geographic market assessment) were ascertained based on a detailed analysis of their respective product offerings, geographic reach/strength (direct or through distributors or suppliers), and the shares of the leading players in a particular region or country.

Breakdown of Primary Interviews

A breakdown of the primary respondents for lateral flow assays market (supply side) market is provided below:

Lateral Flow Assays Market Size, and Share

* Note 1: Others include sales managers, marketing managers, and product managers.

Note 2: Tiers are defined based on a company’s total revenue. As of 2019, Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed wherever applicable.

Approach to derive the market size and estimate market growth

The market rankings for leading players were ascertained after a detailed assessment of their revenues from the lateral flow assays business using secondary data available through paid and unpaid sources. Owing to data limitations, in certain cases, the revenue share was arrived at after a detailed assessment of the product portfolios of major companies and their respective sales performance. At each point, this data was validated through primary interviews with industry experts.

Objectives of the Study

  • To define, describe, analyze, and forecast the lateral flow assays market by product, application, technique, sample type, end user, and region
  • To provide detailed information about the major factors influencing the market growth (drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the global market in North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To analyze the impact of the economic recession on the growth of the global market
  • To strategically profile key players in the global market and comprehensively analyze their core competencies
  • To track and analyze competitive developments such as product launches, expansions, acquisitions, partnerships, agreements, and other developments of leading players in the global market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:

Product Analysis

  • Further breakdown of the kits & reagents segment of the global market
  • Further segmentation of individual product segments by application and end user

Geographic Analysis

  • Further breakdown of the Rest of Asia Pacific market into South Korea, Australia, New Zealand, and others
  • Further breakdown of the Rest of Europe market into Belgium, Russia, the Netherlands, Switzerland, and others

Company Information

  • Detailed analysis and profiling of additional market players (Up to 5)

Maket outlook for the top 10 for Antigen Test Market:

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • F. Hoffmann-La Roche Ltd
  • Quidel Corporation
  • LumiraDx
  • Danaher Corporation
  • Siemens Healthineers
  • Bio-Rad Laboratories, Inc.
  • GenBody Inc.
  • Sysmex Corporation

The global antigen test market is expected to grow significantly due to the ongoing COVID-19 pandemic and the need for rapid testing. The market is also expected to be driven by the increasing prevalence of infectious diseases, rising demand for POC testing, and advancements in technology.

The COVID-19 pandemic has been a significant growth driver for the antigen test market, with increasing demand for rapid antigen tests for the diagnosis of COVID-19. As antigen tests are less expensive and quicker than molecular tests, they are being widely used for mass testing, screening, and surveillance programs.

Additionally, the market is also driven by the increasing prevalence of infectious diseases, such as HIV, hepatitis, and influenza. Antigen tests are being widely used for the detection of infectious diseases, as they provide rapid results and are more affordable than other tests.

Furthermore, the rising demand for POC testing is expected to drive the growth of the antigen test market. POC testing is widely used in clinics, hospitals, and emergency departments, and antigen tests are a popular choice due to their rapid results and ease of use.

However, the market may face challenges such as the high cost of development and manufacturing of antigen tests, lack of awareness and accessibility in certain regions, and stringent regulatory requirements.

In the future, antigen tests are expected to be used for the diagnosis of various diseases and conditions, including cancer, autoimmune diseases, and allergies. The market potential for antigen tests is significant, with increasing demand for rapid, accurate, and cost-effective diagnostic tests.

The risk in the market is mainly related to the uncertainty surrounding the COVID-19 pandemic, which may impact the demand for antigen tests. Additionally, competition among the top players in the market is expected to intensify, with companies investing in research and development to develop new and innovative antigen tests.

Growth drivers for Antigen Test Market from macro to micro

growth drivers for the Antigen Test Market are:

Increased demand due to COVID-19: The COVID-19 pandemic has created a huge demand for antigen tests as they are quick, cost-effective, and offer rapid results. As a result, the market for antigen tests has grown significantly during the pandemic.

Rising prevalence of infectious diseases: Antigen tests are useful in detecting various infectious diseases, including influenza, strep throat, and HIV. The growing prevalence of these diseases is expected to drive the demand for antigen tests in the coming years.

Technological advancements: Technological advancements in the field of diagnostic testing have led to the development of more accurate and reliable antigen tests, which is expected to drive market growth.

Increasing government support: Governments around the world are providing financial support and promoting the use of antigen tests to help contain the spread of COVID-19. This is expected to further boost market growth.

Growing need for point-of-care testing: Antigen tests are convenient and can be performed at the point of care, which eliminates the need for sending samples to a laboratory for testing. This has led to an increased demand for point-of-care testing, which is expected to drive market growth.

Micro factors driving growth in the Antigen Test Market include:

  • Increased awareness among the general public about the benefits of early diagnosis and treatment.
  • The availability of easy-to-use antigen test kits that can be administered by non-specialized healthcare professionals.
  • The growing adoption of antigen tests by hospitals, clinics, and diagnostic centers.
  • The increasing demand for accurate and reliable diagnostic tests.
  • The cost-effectiveness of antigen tests compared to other diagnostic tests.

Hypothetic challenges of Antigen Test Market in future

Potential challenges that the Antigen Test Market may face in the future includes:

False negatives: Antigen tests are generally considered less accurate than PCR tests, and they can produce false negatives in some cases. This means that people who have the virus could receive a negative result and potentially spread it to others.

Quality control issues: Antigen tests are often less sensitive and specific than PCR tests, which means that they may produce more false positives and false negatives. Additionally, there is a risk that poorly manufactured or improperly stored tests could lead to inaccurate results.

Competition from other testing methods: As more testing methods become available, there is a risk that antigen tests could become less popular or lose market share to other options. For example, PCR tests and rapid molecular tests are also used to detect COVID-19.

Changes in testing protocols: As more is learned about COVID-19 and the best ways to control its spread, testing protocols may change. This could lead to a decrease in demand for antigen tests or a shift towards other testing methods.

Regulatory challenges: There may be challenges in obtaining regulatory approval for antigen tests, especially if they are produced by new or less established companies. Additionally, regulatory changes or inconsistencies across different countries or regions could impact the market.

Supply chain issues: The production and distribution of antigen tests may be impacted by supply chain issues, such as shortages of raw materials or difficulties in transporting and storing tests. This could lead to disruptions in the market and make it harder for companies to meet demand.

Future use cases of Antigen Test Market along with commentary of adaption, market potential, risk

potential future use cases of the antigen test market include:

Screening for infectious diseases: Antigen tests can be used to screen individuals for a wide range of infectious diseases, including respiratory viruses, bacterial infections, and sexually transmitted infections.

Testing at point-of-care: Antigen tests are easy to use and can be performed at the point-of-care, making them ideal for use in settings where rapid diagnosis is critical, such as emergency departments, urgent care centers, and primary care clinics.

Mass testing: Antigen tests are relatively inexpensive and can be used to conduct mass testing in populations where outbreaks occur, such as schools, workplaces, and nursing homes.

Surveillance: Antigen tests can be used for surveillance purposes to monitor the prevalence of infectious diseases in a population and to identify emerging outbreaks.

The adaptation and potential of the antigen test market are quite promising, especially in the current scenario where the COVID-19 pandemic has increased the demand for rapid and accurate diagnostic tests. The market potential is expected to grow as the technology for antigen tests continues to improve, making them more accurate and easier to use. However, there are also some potential risks associated with the antigen test market, such as false-positive or false-negative results, inadequate sensitivity, and specificity of the tests, which can lead to misdiagnosis and inappropriate treatment. Additionally, regulatory hurdles and reimbursement issues may impact the growth of the antigen test market.

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 4158
Published ON
Feb, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Lateral Flow Assays Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2023 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback